Complete Up To Date Information about Butatron Tablets.
NADA Number: 044-756 | |
| Proprietary Name |
Butatron® Tablets Tevcodyne Butatron™ |
|---|---|
| Sponsor |
Cross Vetpharm Group Ltd. |
| Sponsor Address |
Broomhill rd. Tallaght, Dublin, 24 IRELAND |
| Ingredients |
Phenylbutazone |
| Species |
Horse, not for meat production Dog, no use class stated or implied |
| Routes of Administration |
Per Os |
| Dose Form |
Tablet |
| Drug Form |
Tablet |
| Dispensing Status |
RX |
|
Dosage Amount, Indications & Limitations |
520.1720a Phenylbutazone tablets and boluses. Specifications: Each tablet contains 100 milligrams, or 1 gram of phenylbutazone. Conditions of use: Dogs Amount: Twenty milligrams per pound of body weight daily. Indications: The drug is used for the relief of inflammatory conditions associated with a musculoskeletal system. Limitations: Administer in three divided doses daily. Do not exceed a total daily dose of 800 milligrams regardless of body weight. Administer at a relatively high dosage level for the first 48 hours and then reduce gradually to a maintenance dosage level with the lowest dosage maintained at a level capable of producing the desired clinical response. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Horses Amount: One to two grams per 500 pounds weight daily. Indications: This drug is used for the relief of inflammatory conditions associated with the musculoskeletal system. Limitations: Do not exceed a daily dosage of 4 grams per day. Administer at a relatively high dosage level for the first 48 hours and then reduce gradually to a maintenance dosage level the lowest dosage maintained at the level capable of producing the desired clinical response. Not for use in animals intended for food purposes. Federal law restricts this drug to use by or on the order of a licensed veterinarian. NAS/NRC status: These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by 514.111 of this chapter, but may require bioequivalency and safety information. |